{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:00:34Z","timestamp":1788091234406,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/wco.0b013e32834a9589","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T05:32:38Z","timestamp":1311831158000},"page":"457-462","source":"Crossref","is-referenced-by-count":40,"title":["Inflammatory myopathies"],"prefix":"10.1097","volume":"24","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210206","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis.","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"R3-8-20210206","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2990.2010.01153.x","article-title":"An update on inflammatory and autoimmune myopathies.","volume":"37","author":"Dalakas","year":"2011","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R4-8-20210206","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coph.2010.03.001","article-title":"Inflammatory muscle diseases: a critical review on pathogenesis and therapies.","volume":"10","author":"Dalakas","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"R5-8-20210206","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0889-857X(02)00021-2","article-title":"Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria.","volume":"28","author":"Mastaglia","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"R8-8-20210206","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis.","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"key":"R9-8-20210206","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ncpneuro0261","article-title":"Sporadic inclusion body myositis: diagnosis, pathogenesis and therapeutic strategies.","volume":"2","author":"Dalakas","year":"2006","journal-title":"Nat Clin Pract Neurol"},{"key":"R10-8-20210206","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncprheum0140","article-title":"Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies.","volume":"2","author":"Dalakas","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R11-8-20210206","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2005.05.003","article-title":"Immunobiology of muscle: advances in understanding an immunological microenvironment.","volume":"26","author":"Wiendl","year":"2005","journal-title":"Trends Immunol"},{"key":"R12-8-20210206","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1016\/S1474-4422(07)70171-0","article-title":"Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.","volume":"6","author":"Needham","year":"2007","journal-title":"Lancet Neurol"},{"key":"R13-8-20210206","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1750-3639.2009.00290.x","article-title":"Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multiprotein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation.","volume":"19","author":"Askanas","year":"2009","journal-title":"Brain Pathol"},{"key":"R14-8-20210206","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of antisignal recognition particle auto-antibody levels with creatine kinase activity in patients with necrotizing myopathy.","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R15-8-20210206","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with antisignal recognition particle antibodies: a case series.","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R16-8-20210206","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrrheum.2010.2","article-title":"Advances in the treatment of myositis.","volume":"6","author":"Dalakas","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R17-8-20210206","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nmd.2005.12.008","article-title":"Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future.","volume":"16","author":"Dalakas","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"R18-8-20210206","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11940-011-0119-8","article-title":"Immunotherapy of inflammatory myopathies: practical approach and future prospects.","volume":"13","author":"Dalakas","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"R19-8-20210206","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1756285608097463","article-title":"Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.","volume":"1","author":"Dalakas","year":"2008","journal-title":"Ther Adv Neurol Disord"},{"key":"R20-8-20210206","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<651::AID-MUS1>3.0.CO;2-7","article-title":"Treatment of inflammatory myopathies.","volume":"20","author":"Mastaglia","year":"1997","journal-title":"Muscle Nerve"},{"key":"R21-8-20210206","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial.","volume":"20","author":"van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"R22-8-20210206","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.nurt.2008.08.008","article-title":"Idiopathic inflammatory myopathies: current and future therapeutic options.","volume":"5","author":"Wiendl","year":"2008","journal-title":"Neurotherapeutics"},{"key":"R24-8-20210206","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis.","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"R25-8-20210206","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","article-title":"Immunoglobulin therapy in inflammatory myopathies.","volume":"65","author":"Mastaglia","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R26-8-20210206","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases.","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"R27-8-20210206","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application.","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R28-8-20210206","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","article-title":"Tacrolimus in refractory polymyositis with interstitial lung disease.","volume":"353","author":"Oddis","year":"1999","journal-title":"Lancet"},{"key":"R29-8-20210206","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as a therapeutic target in autoimmune neurological disorders.","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"R30-8-20210206","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open label pilot study.","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R31-8-20210206","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis.","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"R32-8-20210206","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1756285609356135","article-title":"Practical considerations on the use of rituximab in autoimmune neurological disorders.","volume":"3","author":"Kosmidis","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"R33-8-20210206","first-page":"2080","article-title":"Alemtuzumab (Campath) in the treatment of refractory polymyositis.","volume":"35","author":"Thomson","year":"2008","journal-title":"J Rheumatol"},{"key":"R34-8-20210206","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (Campath 1-H) in patients with inclusion-body myositis.","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"R35-8-20210206","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","article-title":"Successful treatment of dermatomyositis and polymyositis with antitumor necrosis-factor-alpha: preliminary observations.","volume":"50","author":"Hengstman","year":"2003","journal-title":"Eur Neurol"},{"key":"R36-8-20210206","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","article-title":"Refractory polymyositis responding to infliximab: extended follow-up.","volume":"43","author":"Labioche","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R37-8-20210206","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion body myositis with IVIg: a double-blind, placebo-control study.","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"R38-8-20210206","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis.","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology"},{"key":"R39-8-20210206","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/brain\/awn053","article-title":"Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle.","volume":"131","author":"Schmidt","year":"2008","journal-title":"Brain"},{"key":"R40-8-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.21452","article-title":"Interplay between inflammation and degeneration: using inclusion body myositis to study neuroinflammation.","volume":"64","author":"Dalakas","year":"2008","journal-title":"Ann Neurol"},{"key":"R41-8-20210206","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mus.21377","article-title":"Dermatomyositis with inclusion body myositis pathology.","volume":"40","author":"Layzer","year":"2009","journal-title":"Muscle Nerve"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WCO.0b013e32834a9589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:23:31Z","timestamp":1786047811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019052-201110000-00008"}},"subtitle":["management of steroid resistance"],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32834a9589","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}